Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christopher Binette

Vascular Surgery Fort Pierce, FL Medical Doctor

NPI 1922275866 CMS profile 359675

2401 Frist Blvd Ste 4, Fort Pierce, FL 34950

Open in the dashboard

General payments

$31,806

326 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christopher Binette of Fort Pierce, FL is reported in the CMS Open Payments database as having received $31,806 across 326 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,189 55
2024 General $4,622 41
2023 General $6,274 79
2022 General $6,194 57
2021 General $3,342 35
2020 General $1,880 22
2019 General $3,304 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Binette
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Christopher Binette were reported at $6,189. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Christopher Binette Vascular Surgery median Middle half National median
2019 $3,304 $796 $226–$2,363 $163
2020 $1,880 $348 $118–$1,110 $114
2021 $3,342 $471 $158–$1,421 $132
2022 $6,194 $725 $222–$2,183 $149
2023 $6,274 $836 $257–$2,440 $160
2024 $4,622 $909 $252–$2,619 $164
2025 $6,189 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Penumbra, Inc. $9,010 50 payments
  2. W. L. Gore & Associates, Inc. $7,118 77 payments
  3. Endologix, Inc. $2,658 14 payments
  4. Boston Scientific Corporation $2,463 35 payments
  5. Medtronic, Inc. $1,610 15 payments
  6. Silk Road Medical, Inc. $1,488 6 payments
  7. Philips Electronics North America Corporation $957 16 payments
  8. Cook Medical LLC $835 29 payments
  9. Bard Peripheral Vascular, Inc. $729 9 payments
  10. Ge Healthcare $692 2 payments
  11. Other $4,245 73 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $21,623 300 payments
  2. Travel and Lodging $10,133 25 payments
  3. Education $50 1 payment
Products named General payments · program years 2019–2025
  1. Indigo System $8,024 38 payments
  2. ENROUTE Transcarotid Stent $1,488 6 payments
  3. ENROUTE Transcarotid Neuroprotection System $1,488 6 payments
  4. GORE TAG Thoracic Branch Endoprosthesis $1,408 12 payments
  5. GORE TAG Thoracic Endoprosthesis $1,207 8 payments
  6. GORE VIABAHN VBX Balloon Expandable Endo $1,182 11 payments
  7. AFX $844 3 payments
  8. GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis $760 8 payments
  9. EXCLUDER Conformable AAA Endoprosthesis with Active Control $681 7 payments
  10. Pounce Venous Thrombectomy System $619 18 payments
  11. Other $16,004 261 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

241

Median for General Surgery: 59

Drug cost

$57,835

Median for General Surgery: $393

Branded share of claims

100%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 54 $56,172
Clopidogrel Clopidogrel Bisulfate Brand 157 $1,537
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 30 $126

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 116 billing codes

Paid by Medicare

$213,356

Medicare's payments for the services billed

Medicare patients

403

Average age 73

Services billed

1,391

191 women, 212 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 59%
Arthritis 54%
Diabetes 52%
Chronic kidney disease 48%
Heart failure 40%
COPD 34%
Depression 33%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

326 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record